PHESGO (pertuzumab+trastuzumab )1200 мг Roche, Germany
Indications
Early Breast Cancer
PHESGO® (pertuzumab, trastuzumab, and hyaluronidase-zzxf) is indicated for use in combination with chemotherapy for
the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node-positive) as part of a complete treatment regimen for early breast cancer (EBC)
the adjuvant treatment of adult patients with HER2-positive early breast cancer (EBC) at high risk of recurrence
Select patients for therapy based on an FDA-approved companion diagnostic test.
Metastatic Breast Cancer
PHESGO is indicated for use in combination with docetaxel for the treatment of adult patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.
Select patients for therapy based on an FDA-approved companion diagnostic test.
-
Commercial name:Фесго
-
Сhemical name:пертузумаб 1200+трастузумаб 600
-
Dosage:1200 мг
-
Quantity:one
-
Release form:Bottle
-
Производитель:Рош, швейцария